ITCI
Intra-Cellular Therapies, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +13.3% ·
share flow +7.6% ·
net new positions +11.8%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.78M | -5.0% | $234.99M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 190.37K | -81.6% | $25.11M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 3 | T. Rowe Price ✦ | 115.42K | -80.4% | $15.23M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 4 | GAMCO Investors ✦ | 38.10K | New | $5.03M | 0.1% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| GAMCO Investors | $5.03M | 0.1% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1 shares, $2,540 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.